Alirocumab reduces total nonfatal cardiovascular and fatal events the ODYSSEY OUTCOMES trial (2019)
- Authors:
- Autor USP: NICOLAU, JOSÉ CARLOS - FM
- Unidade: FM
- DOI: 10.1016/j.jacc.2018.10.039
- Subjects: ANTICORPOS MONOCLONAIS; DOENÇAS CARDIOVASCULARES; SÍNDROME CORONARIANA AGUDA; ESTATINAS; RESULTADO DE TRATAMENTO
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Título: Journal of the american college of cardiology
- ISSN: 0735-1097
- Volume/Número/Paginação/Ano: v. 73, n. 4, p. 387-396, 2019
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
SZAREK, Michael et al. Alirocumab reduces total nonfatal cardiovascular and fatal events the ODYSSEY OUTCOMES trial. Journal of the american college of cardiology, v. 73, n. 4, p. 387-396, 2019Tradução . . Disponível em: https://doi.org/10.1016/j.jacc.2018.10.039. Acesso em: 26 jan. 2026. -
APA
Szarek, M., White, H. D., Schwartz, G. G., Alings, M., Bhatt, D. L., Bittner, V. A., et al. (2019). Alirocumab reduces total nonfatal cardiovascular and fatal events the ODYSSEY OUTCOMES trial. Journal of the american college of cardiology, 73( 4), 387-396. doi:10.1016/j.jacc.2018.10.039 -
NLM
Szarek M, White HD, Schwartz GG, Alings M, Bhatt DL, Bittner VA, Chiang C-E, Diaz R, Edelberg JM, Nicolau JC. Alirocumab reduces total nonfatal cardiovascular and fatal events the ODYSSEY OUTCOMES trial [Internet]. Journal of the american college of cardiology. 2019 ; 73( 4): 387-396.[citado 2026 jan. 26 ] Available from: https://doi.org/10.1016/j.jacc.2018.10.039 -
Vancouver
Szarek M, White HD, Schwartz GG, Alings M, Bhatt DL, Bittner VA, Chiang C-E, Diaz R, Edelberg JM, Nicolau JC. Alirocumab reduces total nonfatal cardiovascular and fatal events the ODYSSEY OUTCOMES trial [Internet]. Journal of the american college of cardiology. 2019 ; 73( 4): 387-396.[citado 2026 jan. 26 ] Available from: https://doi.org/10.1016/j.jacc.2018.10.039 - P2Y12 inhibitor switching in response to routine notification of CYP2C19 clopidogrel metabolizer status following acute coronary syndromes
- Impact of the Extent of Coronary and Myocardial Disease on the Treatment Effect of Surgical Revascularization in Patients With Ischemic Left Ventricular Dysfunction
- Doença arterial coronariana aguda
- Rationale and design of the long-Term rIsk, clinical manaGement, and healthcare Resource utilization of stable coronary artery dISease in post-myocardial infarction patients (TIGRIS) study
- Ticagrelor versus clopidogrel in patients with STEMI treated with fibrinolysis TREAT trial
- Ticagrelor for the prevention of ischemic events in patients with prior myocardial infarction and peripheral artery disease
- Concomitant proton-pump inhibitor use, platelet activity, and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel and managed without revascularization: Insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes trial
- Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease
- Two-year outcomes among stable high-risk patients following acute MI. Insights from a global registry in 25 countries
- Anti-Thrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC): Study design and methodology for an international, adaptive Bayesian randomized controlled trial
Informações sobre o DOI: 10.1016/j.jacc.2018.10.039 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
